Literature DB >> 35023439

SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).

Irina Kislaya1, Paulo Gonçalves2, Verónica Gómez1, Vânia Gaio1, Rita Roquette1, Marta Barreto1, Mafalda Sousa-Uva1, Ana Rita Torres1, Joana Santos1, Rita Matos2, Carla Manita2, João Almeida Santos2, Sofia Soeiro2, Rita de Sousa2, Inês Costa2, Nuno Verdasca2, Raquel Guiomar2, Ana Paula Rodrigues1.   

Abstract

BACKGROUND: Integrated approaches to surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection are important for public health actions. The 2nd National Serological Survey (ISN2COVID-19) aimed to characterize the extent of SARS-CoV-2 infection and vaccine-induced response in the Portuguese population following the third epidemic wave and the launch of the vaccination campaign.
METHODS: A cross-sectional study was performed using data on 8463 Portuguese 1-79 years of age, collected in February and March, 2021. SARS-CoV-2 IgM and IgG (anti-nucleoprotein and anti-spike) antibodies were determined in serum samples using Abbott Architect chemiluminescent microparticle assays. Post-infection and vaccine-induced seroprevalence with 95% confidence intervals (95%CI) were estimated in the overall sample and stratified by population characteristics.
RESULTS: The estimated seroprevalence was 15.5% (95%CI:14.6-16.5%), of which 13.5% (95%CI: 12.6-14.4%) was attributable to natural infection and 2.0% (95%CI:1.7-2.4%) to vaccination. The lowest seroprevelence was observed in persons aged 70-79 years (8.9% 95%CI:6.8-11.6), while seroprevalence in children (14.3%; 95%CI:11.5-17.6%) and adolescents (12.9%; 95%CI:10.5-15.7%) was similar to that of persons aged between 20 and 69 years. Of seropositive individuals, 22.6% (95%CI:19.7-25.9%) did not report any symptoms in 6 months prior to interview. Of persons with completed vaccination (2-doses), 98.6% (95%CI: 93.0-99.7%) had specific IgG (anti-S) antibodies.
CONCLUSIONS: After the third epidemic wave, the post-infection SARS-CoV-2 seroprevalence was 1.7 times higher than the cumulative incidence based on PCR-testing, but was higher (2.7 times) in children may be due to the high proportion of asymptomatic and mild infections.

Entities:  

Keywords:  COVID-19; Portugal; Seroprevalence; seroepidemiological survey; severe acute respiratory syndrome coronavirus 2

Mesh:

Substances:

Year:  2022        PMID: 35023439     DOI: 10.1080/23744235.2021.2025421

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  4 in total

1.  Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey.

Authors:  Lara E Coelho; Paula M Luz; Débora C Pires; Emilia M Jalil; Hugo Perazzo; Thiago S Torres; Sandra W Cardoso; Eduardo M Peixoto; Sandro Nazer; Eduardo Massad; Mariângela F Silveira; Fernando C Barros; Ana T R Vasconcelos; Carlos A M Costa; Rodrigo T Amancio; Daniel A M Villela; Tiago Pereira; Guilherme T Goedert; Cleber V B D Santos; Nadia C P Rodrigues; Beatriz Grinsztejn; Valdilea G Veloso; Claudio J Struchiner
Journal:  Lancet Reg Health Am       Date:  2022-07-30

2.  Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.

Authors:  Stefania Paduano; Pasquale Galante; Nausicaa Berselli; Luca Ugolotti; Alberto Modenese; Alessandro Poggi; Marcella Malavolti; Sara Turchi; Isabella Marchesi; Roberto Vivoli; Paola Perlini; Rossana Bellucci; Fabriziomaria Gobba; Marco Vinceti; Tommaso Filippini; Annalisa Bargellini
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

3.  A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021.

Authors:  Kento T Abe; Bhavisha Rathod; Karen Colwill; Anne-Claude Gingras; Ashleigh Tuite; Ninette F Robbins; Guillermo Orjuela; Craig Jenkins; Valerie Conrod; Qi-Long Yi; Sheila F O'Brien; Steven J Drews
Journal:  Microbiol Spectr       Date:  2022-06-02

Review 4.  SARS-CoV-2 Seroprevalence in Those Utilizing Public Transportation or Working in the Transportation Industry: A Rapid Review.

Authors:  Aliisa Heiskanen; Yannick Galipeau; Marc-André Langlois; Julian Little; Curtis L Cooper
Journal:  Int J Environ Res Public Health       Date:  2022-09-15       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.